flavin-mononucleotide and Infant--Premature--Diseases

A multicenter trial involving 30 newborns with post-hypoxic myocardial lesions associated with I-II degree cerebral ischemia has revealed that the inclusion of cytoflavin infusions into the complex standard treatment leads, besides the improvement of general clinical status, to significantly more rapid, as compared to the control group, positive dynamics of pump and contractile myocardial functions, elimination of hyperenzymemia, hypoxia and electrical instability of the myocardium, decrease in energetic deficit, and repolarization changes within the first 5 days of in-hospital therapy as well as during the follow-up from 1 to 6 months of life.

Topics: Brain Ischemia; Drug Combinations; Female; Flavin Mononucleotide; Follow-Up Studies; Heart; Humans; Infant, Newborn; Infant, Premature; Infant, Premature, Diseases; Inosine Diphosphate; Male; Myocardial Contraction; Myocardium; Niacinamide; Succinates